All trademarks, trade names and service marks appearing in this presentation are the property of their respective owners. Forward-Looking Statement Safe-Harbor This presentation contains forward-looking statements about

February 2018 2018: MILESTONES ON THE

HORIZON Exhibit 99.1

All trademarks, trade names and service

marks appearing in this presentation are the property of their respective owners. Forward-Looking Statement Safe-Harbor This presentation contains forward-looking statements about Minerva Neurosciences which are subject to the safe harbor provisions

of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this presentation, and involve certain risks and

uncertainties. Forward-looking statements include, but are not limited to: the benefits, efficacy and safety of our new formulations; whether studies performed on analogs or backups of our compounds are a good predictor of the clinical efficacy of

our compounds; statements with respect to the timing and results of future clinical milestones with MIN-101, seltorexant (MIN-202), MIN-117 and MIN-301, including the Phase 3 trial of MIN-101; the Phase 2b trials of seltorexant; the planned Phase 2b

trial of MIN-117; statements regarding our ability to successfully develop and commercialize our therapeutic products; our ability to expand our long-term business opportunities; our expectations regarding approval for our products by the U.S. Food

and Drug Administration or equivalent foreign regulatory agencies; estimates regarding the market potential for our products; financial projections and estimates and their underlying assumptions; and future performance. All of such statements are

subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the

forward-looking statements. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether any of our therapeutic products will

advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether the results of

future clinical trials of MIN-101, seltorexant, MIN-117 and MIN-301, if any, will be consistent with the results of past clinical trials; whether MIN-101, seltorexant, MIN-117 and MIN-301 will be successfully marketed if approved; whether our

therapeutic product discovery and development efforts will be successful; our ability to achieve the results contemplated by our co-development agreements; the strength and enforceability of our intellectual property rights; competition from

pharmaceutical and biotechnology companies; the development of and our ability to take advantage of the market for our therapeutic products; our ability to raise additional capital to fund our operations on terms acceptable to us; and general

economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and

Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, filed with the Securities and Exchange Commission on November 6, 2017. Copies of reports filed with the SEC are posted on our website at

www.minervaneurosciences.com. Our audience is cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as

Innovative pipeline of four compounds

and multiple indications in the CNS space Program Primary Indications MoA Pre- clinical Phase 1 Phase 2 Phase 3 MIN-101 Negative symptoms in Schizophrenia 5-HT2A antagonist Sigma2 antagonist Seltorexant MIN-202 Primary Insomnia Major

Depressive Disorder as adjunctive therapy Selective Orexin2 antagonist MIN-117 Major Depressive Disorder in monotherapy 5-HT1A 5HT transporter Alpha-1a, b Dopamine transporter 5-HT2A antagonist MIN-301

Parkinson's Disease Neuregulin 1 1 activating ErbB4 Phase 3 initiated Dec 2017 (MIN-101C07) Phase 2b initiated Dec 2017 (ISM2005) Pre-clinical Phase 2b planned H1 2018 (MIN-117C03) Phase 2b initiated Sep 2017 (MDD2001) Phase 2b

initiated Dec 2017 (MDD2002)

Three programs and five clinical trials

Lead program MIN-101: Negative symptoms in schizophrenia, monotherapy MIN-101C07 Phase 3 ongoing (~500 patients worldwide) Seltorexant (MIN-202): Primary insomnia and major depressive disorder (MDD) MDD2001 Phase 2b ongoing in adjunctive MDD &

placebo (~280 patients worldwide) MDD2002 Phase 2b ongoing in adjunctive MDD & comparator (~100 patients U.S.) ISM2005 Phase 2b ongoing in insomnia monotherapy (~360 patients worldwide) MIN-117: MDD with prominent anxiety in monotherapy

MIN-117C03 Phase 2b expected to begin in early 2018 (~325 patients worldwide)

MIN-101 A new paradigm for the

treatment of schizophrenia

Market Landscape: Schizophrenia (US)

Burden of disease and market potential

59% of adult patients with

schizophrenia who are treated have negative symptoms and are clinically stable 15%2,3 weighted-average 6-month relapse rate among patients with varying severity of negative symptoms 69% of patients have negative symptoms: ~42%2,3 predominant/

prominent symptoms; ~27%4 mild symptoms 1.Wu et al., Psychol Medicine 2006; 2. Millier et al., J Market Acc Health Policy, 2017; 3. Haro et al., Schizo Research 2015 ; 4. Nordstroem et al., J Social Psychiatry 2017 Prevalence of US adults with

schizophrenia in treatment/yr: 0.53%1 Schizophrenia.com: 2.2 million patients in U.S. Estimated prevalence Of SZ (0.88%) 2.2 million US adults Treatment prevalence of SZ (0.53%) 1.3 million US adults Negative Sx (69%) 919,553 US adults Stable

patients (85%): 781,620 US adults

Severity of Illness Chronic Progression

of Negative Symptoms & Cognitive Impairment Youth 0-18 Adult 18-40 Mature >40 Cognitive Symptoms Negative Symptoms Positive Symptoms Intermittent acute episodes of positive symptoms decline in frequency and severity Negative symptoms and

cognitive impairment are evident at onset of illness and are lifelong debilitating symptoms All antipsychotics directly target dopamine (DA) receptors and have only shown efficacy against positive symptoms; none are indicated for negative symptoms

or cognitive impairment Source of chart and captions: Minerva Corporate Presentation. Slide 7. January 2018. Source of bullets: KOL Exploratories. January 9-10, 2018. Cello Health Advantage Inc. Both cognitive deficits and negative symptoms usually

exist before 18 y Some experts note that not all positive symptoms are episodic; for some patients, positive symptoms may decline more gradually, and some patients can achieve full remission Positive symptoms fluctuate over time while negative and

cognitive symptoms persist and cause lifelong disability

Total SZ sales for oral tablet: $1.41

billion Recent survey of psychiatrist ranks negative symptoms as #1 unmet medical need for patients with schizophrenia

The economic burden of schizophrenia

includes1: The economic burden is particularly great during the first year following the index episode, mainly due to higher hospitalization rates vs chronic patients2 The average annual healthcare costs of newly diagnosed patients are $20,654 vs

$15,489 for chronic patients2 There is also a great burden to caregivers including loss of productivity and emotional stress2 WHO estimates that the direct costs of schizophrenia range from 1.6% to 2.6% of total healthcare expenditures in western

countries3 WHO indicates World Health Organization. 1. Cloutier M, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016 Jun:77(6):764-71. https://www.ncbi.nlm.nih.gov/pubmed/27135986. Accessed December

29, 2017. 2. Nicholl D, Akhras KS, Diels J, Schadrack J. Burden of schizophrenia in recently diagnosed patients: Healthcare utilization and cost perspective. Curr Med Res Opin 2010;26:943-955.

https://www.ncbi.nlm.nih.gov/pubmed/20163295. Accessed December 29, 2017. 3. WHO. Nations for Mental Health. Schizophrenia and public health. http://www.who.int/mental_health/media/en/55.pdf?ua=1. Accessed December 29, 2017. Direct nonhealthcare

costs include: Law enforcement, homeless shelters, research, and training Indirect costs include: Loss of productivity, premature mortality (suicide), and caregiving The total economic burden of schizophrenia in the US is high, estimated to be

MIN-101: Phase 2b study design:

monotherapy, double-blind, placebo-controlled in schizophrenic patients with confirmed negative symptoms MIN-101 64mg (n = 83) Screening Treatment & Assessments 4 weeks Screening 12 week double-blind phase core study' 24

week open-label extension' phase Placebo (n = 83) MIN-101 32mg (n = 78) R MIN-101 64mg MIN-101 32mg Crossover Randomization Specific effects on negative symptoms can only be determined in a placebo-controlled study

Phase 2b study showed specific

improvements in negative symptoms over 12 weeks and 36 weeks in both doses and stable positive symptoms Core Phase Extension Phase PANSS Positive Symptoms Subscale Change from Baseline PANSS Negative Symptoms Subscale Change from Baseline

Statistically significant improvements in the primary endpoint Extension

MIN-101 Phase 2b: American Journal

of Psychiatry 2017; 00:1- 8

MIN-101: Phase 3 initiated December

Phase 3 efficacy study: confirmatory

study design guided by insights from Phase 2b and dialogue with FDA Primary endpoint: PANSS Negative Symptoms Factor Score (NSFS) according to Marder after 12 weeks administration Secondary endpoints: Clinical Global Impression of Severity (CGI-S)

and Personal and Social Performance scale (PSP) 40 weeks (9 months) open-label extension 501 patients randomized 1:1:1 to 32mg & 64mg doses of MIN-101 vs placebo Symptomatically stable patients for several months with moderate to severe negative

symptoms (>20 PANSS NSFS) and stable positive symptoms If patients are on antipsychotic medication, switch to MIN-101 without long wash-out periods so as to mimic clinical practice Study carried out in US (approx 30% of patients) and Europe

MIN-101 Phase 3 study design:

monotherapy, double-blind, placebo-controlled in schizophrenic patients with negative symptoms MIN-101 64mg (n = 167) Screening Treatment & Assessments 4 weeks Screening 12 week double-blind phase core study' 40 week

open-label extension' phase Placebo (n = 167) MIN-101 32mg (n = 167) R MIN-101 64mg MIN-101 32mg Crossover Randomization Phase 3 compared to Phase 2b: same patient population; same double-blind duration; same doses; PANSS negative score

primary endpoint; CGI & PSP secondary endpoints; 40 weeks extension allows 1 year safety coverage

Competitive landscape

MIN-101: general dynamics of the

schizophrenia market MIN-101 is unique in the late-stage schizophrenia pipeline: a monotherapy targeting negative symptoms in maintenance phase Phase 3 studies: Acute Phase 3 studies: Maintenance & Sub-population studies Negative Symptoms,

Treatment-resistance, Residual positive symptoms, and Niche populations Long-Acting Injectables or Patch Source: Jan 2018; Cambridge Healthcare Research (CHR) Limited, www.camhcr.com; ClinicalTrials.gov ITI-007 (lumateperone) (5-HT2A antagonist, D2

/D1 modulator, SSRI) ALKS 3831 (Mu-opioid antagonist + olanzapine) Risperidone implant (6 monthly, nonbiodegradable risperidone drug-eluting stent) RBP-7000 (once-monthly, SR risperidone) HP 3070 (transdermal patch of asenapine) MIN-101 (5-HT2A

& 2R antagonist) Risperidone ISM (once-monthly IM risperidone) Lu AF35700 (D1, 5-HT2A & 5-HT6 antagonist) ACP-103 (pimavanserin) (5-HT2A inverse agonist) NaBen (sodium benzoate) (D-amino acid oxidase inhibitor) Indications Three

late-stage indications: -Residual positive symptoms, adjunctive use -Adolescents, monotherapy -Clozapine refractory, adjunctive use -Residual positive symptoms, adjunctive use -Treatment-resistant, monotherapy study vs. risperidone and olanzapine

-Negative symptoms, monotherapy

MIN-101: general dynamics of the

schizophrenia market MIN-101 is positioned to launch without competitors in negative symptoms as it is the only compound in Phase 3 and sole study in monotherapy Clinical Trials in Negative Symptoms in Schizophrenia in ClinicalTrials.Gov Phase 3 in

Negative Symptoms Phase 2 in Negative Symptoms Source: Clinical Trials.gov accessed Feb 13, 2018. MIN-101 (monotherapy) 5-HT2A & 2 receptors antagonist ACP-103 (adjunctive use) 5-HT2A inverse agonist, Ph2 anticipated to complete in June

2019 Companies & Compounds Phase 3 study: Study results anticipated by June 2019 Primary endpoint: Negative Symptoms Factor Score (NSFS) of the Positive and Negative Symptoms Scale (PANSS) Secondary endpoints: Personal and Social Performance

(PSP) scale, measure of functioning Clinical Global Impression - Severity (CGI-S), clinician rated overall severity of schizophrenia LY500307 (adjunctive use) Selective estrogen receptor agonist, Ph2a anticipated to complete in June 2018

AVP-786 (adjunctive use) Fixed dose quinidine + dextromethorphan (weak NMDA antagonist + 1 R agonist), Ph2 completed Aug 2017, awaiting results TAK-831 (adjunctive use) DAAO inhibitor, Ph2 anticipated to complete April 2020 Exploratory Phase 4

academic driven studies on ClinicalTrials.Gov (Feb 13, 2018): Vortioxetine adjunctive use, Ph4 n=88, study to complete by 03/20, sponsor: Zucker Hillside Hospital Memantine adjunctive use, Ph4 n=120, study to complete by 12/17, sponsor: National

Taiwan University Hospital N-acetylcysteine adjunctive, Ph4 n=40, study to complete by 12/17, sponsor: UCLA

A drug to treat insomnia & major

depressive disorder by restoring physiological sleep A co-development/co-commercialization program with: Seltorexant MIN-202 / JNJ42847922

Name MoA PK/PD profile Depressive

Symptom Orexinergic Domain Depression/Irritability Emotion/Arousal Low Self View/Guilt Emotion Loss of Interest & Pleasure Reward/Motivation Suicide/Death Ideation Reward/Motivation Sleep Disturbance Sleep-Wake Agitation, Restlessness

Arousal/Energy Balance Orexin system: neurobiology targets circuits that mediate sleep and mood symptoms 21 Seltorexant Selective Orexin-2 Antagonist Highly selective for Orexin-2 (relative to Orexin-1) Short Tmax (30 minutes) - produces rapid onset

of effect Short half-life (2 hours) - minimizes daytime "hangover"

Seltorexant studies in MDD with

comorbid insomnia shows improvements of insomnia and depressive symptoms

Seltorexant Phase 2b program: two

trials in MDD and one in Insomnia ongoing First MDD trial initiated Sep 2017 (clinicaltrials.gov: NCT03227224) Double-blind, randomized, parallel-group, placebo-controlled adaptive-dose finding study 4-week screening, 6-week double-blind treatment

and 2-week follow-up ~ 280 patients planned to be enrolled at >85 clinical sites in the U.S., Europe, Russia and Japan - safety & tolerability and dose response and efficacy in up to 3 doses of seltorexant Second MDD trial initiated Dec 2017

(clinicaltrials.gov: NCT03321526) Double-blind, randomized, flexible-dose parallel-group study 4-week screening, 6-month double-blind treatment and 2-week follow-up ~ 100 patients planned to be enrolled at ~34 clinical sites in the U.S. - assess the

efficacy of flexibly dosed seltorexant compared to flexibly dosed quetiapine as adjunctive therapy to baseline antidepressant therapy (either an SSRI or SNRI) in delaying time to all-cause discontinuation of study drug over a 6-month treatment

period Insomnia trial initiated Dec 2017 (clinicaltrials.gov: NCT03375203) Double-blind, randomized, parallel-group, active- and placebo-controlled dose finding study Up to 61-day duration, including screening and follow-up ~ 360 patients planned to

be enrolled at clinical sites in the U.S., Europe and Japan - assess the dose-response of three doses of seltorexant compared to placebo on sleep onset as measured by latency to persistent sleep (LPS) using polysomnography (PSG) - assess the

dose-response of these doses compared to placebo on wake after sleep onset (WASO) over the first six hours using PSG) - compare the effects of seltorexant on sleep and cognition to those effects of zolpidem